Literature DB >> 11895378

A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch.

Zareen Amtul1, Patrick A Lewis, Sian Piper, Richard Crook, Matt Baker, Kirk Findlay, Andrew Singleton, Marion Hogg, Linda Younkin, Steven G Younkin, John Hardy, Michael Hutton, Bradley F Boeve, David Tang-Wai, Todd E Golde.   

Abstract

A novel presenilin 1 mutation, insR352, associated with a frontal temporal dementia phenotype has been identified (E. A. Rogaeva et al., 2001, Neurology 57, 621-625). This mutation does not increase Abeta42 levels, but instead acts as dominant negative presenilin, decreasing amyloid beta protein (Abeta) production by inhibiting gamma-secretase cleavage of the Abeta precursor. The distinct clinical phenotype associated with this mutation suggests that chronic partial inhibition of gamma-secretase activity may result in neurodegeneration. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895378     DOI: 10.1006/nbdi.2001.0473

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  21 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 3.  The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.

Authors:  Jie Shen; Raymond J Kelleher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

4.  Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1.

Authors:  Omar Nelson; Huiping Tu; Tianhua Lei; Mostafa Bentahir; Bart de Strooper; Ilya Bezprozvanny
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

Review 5.  Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease.

Authors:  Bart De Strooper
Journal:  EMBO Rep       Date:  2007-02       Impact factor: 8.807

6.  Pharmacological and genetic reversal of age-dependent cognitive deficits attributable to decreased presenilin function.

Authors:  Sean M J McBride; Catherine H Choi; Brian P Schoenfeld; Aaron J Bell; David A Liebelt; David Ferreiro; Richard J Choi; Paul Hinchey; Maria Kollaros; Allison M Terlizzi; Neal J Ferrick; Eric Koenigsberg; Rebecca L Rudominer; Ai Sumida; Stephanie Chiorean; Kathleen K Siwicki; Hanh T Nguyen; Mark E Fortini; Thomas V McDonald; Thomas A Jongens
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

Review 7.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

8.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.

Authors:  Miguel A Riudavets; Leonardo Bartoloni; Juan C Troncoso; Olga Pletnikova; Peter St George-Hyslop; Marcelo Schultz; Gustavo Sevlever; Ricardo F Allegri
Journal:  Brain Pathol       Date:  2013-04-25       Impact factor: 6.508

10.  Intracellular calcium deficits in Drosophila cholinergic neurons expressing wild type or FAD-mutant presenilin.

Authors:  Kinga Michno; David Knight; Jorge M Campusano; Jorge M Campussano; Diana van de Hoef; Gabrielle L Boulianne
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.